Protease-sparing regimen

Protease-sparing regimen, often abbreviated as PSR, is a method or therapy for treating people infected with HIV that involves a three-drug combination that reduces viral load below the limit of detection while saving protease inhibitors for later use. It is considered a weaker (in terms of quantity and concentration) form of HIV treatment. It has been argued that such a regimen is not as potent as giving HIV patients with the strongest drugs as soon as it is detected. Others believe that this might be considered a long-term strategy in order to reduce the amount of HIV,[1] and in some instances have proven to be successful.[2]

See also

References

  1. ↑ Corales RB, Shrestha NK, Taege AJ, et al. (2001). "Protease-sparing regimen in a real-life practice with naïve patients: an equal opportunity approach?". HIV Clin Trials 2 (1): 17–21. PMID 11590510.
  2. ↑ Van der Linden D, Hainaut M, Goetghebuer T, et al. (April 2007). "Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants". Pediatr. Infect. Dis. J. 26 (4): 359–61. doi:10.1097/01.inf.0000258626.34984.eb. PMID 17414406.
This article is issued from Wikipedia - version of the Wednesday, September 02, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.